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BACKGROUND: The study was performed to determine detection rate and prognostic relevance of disseminated tumour cells (DTC) in
patients receiving curatively intended surgery for colorectal cancer (CRC).
METHODS: The study population consisted of 235 patients with CRC prospectively recruited from five hospitals in the Oslo region.
Bone marrow (BM) aspirates were collected at the time of surgery and the presence of DTC was determined by two immunological
methods; immunomagnetic selection (using an anti-EpCAM antibody) and immunocytochemistry (using a pan-cytokeratin antibody).
Associations between the presence of DTC and metastasis-free, disease-specific and overall survival were analysed using univariate
and multivariate methods.
RESULTS: Disseminated tumour cells were detected in 41 (17%) and 28 (12%) of the 235 examined BM samples by immunomagnetic
selection and immunocytochemistry, respectively, with only five samples being positive with both methods. The presence of DTC
was associated with adverse outcome (metastasis-free, disease-specific and overall survival) in univariate and multivariate analyses.
CONCLUSION: The presence of DTC was associated with adverse prognosis in this cohort of patients curatively resected for CRC,
suggesting that DTC detection still holds promise as a biomarker in CRC.
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In colorectal cancer (CRC), treatment decisions are still made
almost exclusively based on clinicopathological parameters as
described by Dukes almost a century ago (Dukes, 1932), and the
search for prognostic biomarkers to improve patient stratification
for adjuvant treatment and intensified postoperative surveillance is
highly warranted. Despite advances in diagnosis and treatment, a
significant proportion (up to 50%) of curatively resected patients
develops disease recurrence, primarily as liver and lung metastases
(O’Connell et al, 2004; Pfister et al, 2004). Metastasis development
in patients without discernable metastatic disease at the time of
primary surgery reflects preceding dissemination of tumour cells
with metastatic properties to target organs. Over the last couple of
decades, the identification of tumour cells in blood and bone
marrow (BM) has been proposed as a potential biomarker of
adverse prognosis in solid tumours (Pantel et al, 2009). Analyses of
tumour cells derived from blood and BM suggest that micro-
metastases represent a heterogeneous species of cells, possibly not
responsive to classic chemotherapeutic strategies. Thus, in
addition to being used as a potential biomarker, the possibility
of molecular characterisation of the cells might pave the way for
therapy specifically targeting such cells, since current treatment
options seem to offer limited efficacy with respect to eradicating
and controlling this type of disseminated disease.
We previously investigated the presence of disseminated tumour
cells in BM (DTC) in 316 patients with assumed CRC using
immunomagnetic selection (IMS) with the anti-EpCAM antibody
MOC31. Disseminated tumour cells were detected in 17% of
patients with CRC with increasing frequency through TNM stages
1–3 (Flatmark et al, 2002). In the present work, we present long-
term follow-up for this patient cohort, and additionally, we report
results obtained by immunocytochemistry (ICC) with anti-
cytokeratin antibodies.
PATIENTS AND METHODS
Patients
Patients undergoing surgery for assumed or verified CRC were
included consecutively from five hospitals in the Oslo region
between September 1998 and July 2000. The study was approved by
the Regional Ethics Committee (Health Region II, Norway,
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sreference no. S-98080), and patient informed consent was obtained
in accordance with the Helsinki Declaration. Bone marrow was
collected at primary surgery from both anterior iliac crests from
316 patients. Eighty-one patients were excluded from the analysis,
leaving a study population of 235 patients (not invasive cancer
(n¼25); insufficient material for analysis (n¼2); previous
epithelial cancer (n¼7); histology other than adenocarcinoma
(n¼5); neoadjuvant chemoradiotherapy (n¼2); incomplete
surgical resection (n¼7); or metastases detected at the time of
surgery (n¼33)). Follow-up data were obtained from consecutive
reports from physicians at participating hospitals. Valid observa-
tions of the presence or absence of distant metastases required
radiological examination. For patients not attending scheduled
controls, data were retrieved from patient records or by contacting
the patients’ general practitioner. In addition, survival data were
obtained from the National Registry of Norway and updated by 1
October 2008. The cause of death was classified as death from CRC,
death of other causes or death of unknown cause. For overall
survival, median follow-up of patients still alive was 9.3 years
(range 8.3–10.2). Histological evaluation of resected specimens
was performed in four pathology laboratories, and to ensure
consistent staging and grading, one of the study pathologists
(JMN) reevaluated reports and primary sections, simultaneously
reassessing the presence or absence of lymphocyte infiltration,
vascular and perineural invasion and perinodal growth (Table 1).
Immunomagnetic selection with an anti-EpCAM antibody
Immunomagnetic selection was performed as previously described
(Flatmark et al, 2002). Briefly, mononuclear cells (MNCs) were
separated from BM by gradient centrifugation using CPT tubes
(Becton Dickinson Co., Franklin Lakes, NJ, USA), washed once and
resuspended in PBS with 1% HSA (Octapharma AG, Ziegelbru ¨cke,
Switzerland). Dynabeads M450 rat antimouse IgG1 or M450 sheep
antimouse IgG (Dynal, Oslo, Norway) coated with MOC31
antibody (IQ Products, Groningen, The Netherlands) were added
to 2 10
7 MNCs at a ratio of one bead to two MNCs in a total
volume of 1ml in 10ml, round-bottomed test tubes. For control
experiments, uncoated beads were used. Samples were incubated at
continuous rotation at 41C for 30min, and the suspension was then
exposed to a strong magnet, and the supernatant was decanted off.
Fractions of the remaining cell suspension were examined in a
light microscope for the presence of rosetted cells. A sample was
classified as positive if a minimum of two cells rosetted at least five
beads with the MOC31 antibody, and no rosettes were observed
with the control beads.
Immunocytochemistry with anti-cytokeratin antibodies
Direct cytospins were prepared by centrifuging MNC isolated from
BM onto glass slides using a Hettich cytocentrifuge (Tutlingen,
Germany). The slides were air-dried overnight and stored at
 801C. Immunocytochemistry was performed as described pre-
viously by incubating four slides (2 10
6 MNC) with anti-
cytokeratin monoclonal antibodies AE1 and AE3 (Sanbio, Uden,
The Netherlands) and the same number of slides were incubated
with an isotype-specific irrelevant control antibody (MOPC-21;
Sigma Chemical Co., St Louis, MO, USA). Slides were evaluated by
light microscopy and cytokeratin-positive cells were subjected to
strict morphological classification by a pathologist (EB) according
to standardised criteria (Borgen et al, 1999; Fehm et al, 2006).
Statistical analysis
Associations between the presence of DTC and clinicopathological
variables were tested using two-tailed Fisher’s exact test or linear-
by-linear association w
2-test. Univariate survival analysis was
performed according to the Kaplan–Meier method, and survival
was compared using the log rank test. Multivariate analysis was
conducted using the Cox proportional hazards regression model
with backward, stepwise elimination of variables. Survival was
measured from the date of surgery until death for overall and
disease-specific survival, and from the date of surgery until
diagnosis of distant metastasis for metastasis-free survival. Data
analysis was performed using SPSS version 16.0 (SPSS Inc.,
Chicago, IL, USA). P-values o0.05 were considered statistically
significant.
RESULTS
Patient characteristics and outcome
Clinical and histological parameters of the study population are
summarised in Table 1. Mean age at the time of surgery was 72
years (range 35–98 years). Twenty-nine patients in TNM stage 3
(40%) and two patients in stage 2 (2%) received adjuvant
chemotherapy. Tumour perforation at surgery occurred in three
rectal cancer patients (two with stage 2 and one stage 3 tumour),
and adjuvant radiotherapy was given in these cases. Only 8 of the
69 patients with DTC received adjuvant chemotherapy. Outcome
parameters are presented in Table 2. Fifty-five patients developed
distant metastases during follow-up (after median 15 months,
range 1–59 months), 31 of which had colon cancer and 24 had
rectal cancer. A total of 51 CRC-related deaths were registered, and
48 of these patients died of metastatic disease, whereas 3 died of
local recurrence. (A discrepancy is apparent between present
results and published data (Flatmark et al, 2002), as two IMS
negative patients previously incorrectly registered as TNM stage 2
have been corrected to TNM stage 1 (as these corrections
represented changes at the decimal level, no erratum was
published).)
Detection of DTC
Using the IMS method, EpCAM-positive tumour cells were
detected in 41 BM samples (17%) with increasing frequency
through TNM stages 1–3; 10%, 18% and 22%, respectively. A
median number of 8 tumour cells (range 2–120) were detected in
positive samples. Cytokeratin-positive cells were detected in 28
samples (12%) with relatively low detection rate (8%) in TNM
stage 2, whereas 14% and 17% of samples were positive in stages 1
and 3, respectively. The median number of tumour cells detected
by ICC was 1 (range 1–30), and in 21 of the 28 positive samples
only one tumour cell was observed. Of note, only five patients were
positive with both methods (one in TNM stage 2 and four in stage
3 patients). The presence of DTC was not associated with any of
the clinicopathological variables studied (Table 3).
Clinicopathological parameters and patient outcome
In univariate analysis, TNM stage, lymph node metastases, tumour
localisation in the rectum, absence of tumour lymphocyte
infiltration and presence of vascular invasion were associated
with metastasis development (Table 4). The presence of lymph
node metastases was the main contributor to the prognostic
impact of TNM stage, which was also associated with disease-
specific and overall survival, while pT-stage was not associated
with any of the included outcome parameters. The prognostic
relevance of tumour localisation was confined to the distinction
between colon and rectum. No significant prognostic differences
were observed between the presence of left-sided and right-sided
tumours (data not shown). Lymphocyte infiltration, vascular
invasion and perineural invasion were associated with disease-
specific survival but not with overall survival.
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The detection of tumour cells in BM was associated with adverse
prognosis in this cohort of CRC patients (Figure 1; Table 4). The
presence of EpCAM-positive cells, as detected by IMS, was
inversely associated with metastasis-free, disease-specific and
overall survival in univariate analyses (P-values 0.049, 0.03 and
0.02, respectively). Immunocytochemistry detection of cytoker-
atin-positive cells was inversely associated with metastasis-free and
disease-specific survival, but not with overall survival (P-values
0.03, 0.002 and 0.06, respectively). In multivariate Cox regression
analyses, the impact of detecting EpCAM-positive cells in BM
remained evident for metastasis-free survival (Table 4), as well as
for disease-specific (P¼0.002; HR¼3.0; CI¼1.5–5.8) and overall
survival (P¼0.006; HR¼1.9; CI¼1.2–3.0). For cytokeratin-
positive cells, an association was preserved in multivariate analysis
only for disease-specific survival (P¼0.01; HR¼2.5; CI¼1.2–5.0).
Table 2 Detection of disseminated tumour cells and patient outcome
parameters
Patients
Number %
EpCAM-positive cells (immunomagnetic selection)
Negative 194 83
Positive 41 17
Positive samples TNM stage 1 5 10
Positive samples TNM stage 2 20 18
Positive samples TNM stage 3 16 22
Cytokeratin-positive cells (immunocytochemistry)
Negative 197 84
Positive 28 12
ND 10 4
Positive samples TNM stage 1 7 14
Positive samples TNM stage 2 9 8
Positive samples TNM stage 3 12 17
Distant metastases
Yes 55 23
No 180 77
Local recurrence
a
Yes 10 4
No 225 96
Death
Yes 113 48
No 122 52
Cause of death
Colorectal cancer 51 22
Other 33 14
Unknown 29 12
Location of metastases
b
Liver 33
Lungs 26
Other location 21
aSix patients had isolated local recurrence.
bMetastases in more than one location
were diagnosed in 22 patients.
Table 3 Associations between detection of disseminated tumour cells
in bone marrow and clinicopathological parameters
P-value
a
IMS ICC
Gender 0.61 1.0
TNM 0.08 0.49
pT 0.29 0.88
pN 0.08 0.37
Differentiation 0.81 0.28
Tumour localisation 0.36 0.19
Lymphocyte infiltration 0.77 0.15
Vascular invasion 1.0 0.11
Neural invasion 0.21 0.71
Perinodal growth
b 0.57 0.34
IMS NA 1.0
ICC 1.0 NA
Abbreviations: ICC¼immunocytochemistry; IMS¼immunomagnetic selection;
NA¼not applicable.
aP-values are from Fisher’s exact test or linear-by-linear
association w
2-test.
bPerinodal growth was assessed in node-positive patients only.
Table 1 Baseline clinicopathological characteristics of the study cohort
Patients
Parameter Number %
Total 235 —
Gender
Female 106 45
Male 129 55
TNM
15 2 2 2
2 111 47
37 2 3 1
pT
18 3
24 9 2 1
3 154 66
42 4 1 0
pN
0 163 69
14 7 2 0
22 5 1 1
Differentiation
Well 7 3
Intermediate 203 86
Poor 25 11
Tumour localisation
Colon 160 68
Rectum 75 32
Lymphocyte infiltration
High 28 12
Intermediate 152 65
Low 52 22
ND 3 1
Vascular invasion
Absent 189 80
Present 45 19
ND 1 0.4
Neural invasion
Absent 215 92
Present 19 8
ND 1 0.4
Perinodal growth
a
Absent 30 42
Present 42 58
Abbreviation: ND¼not done.
aPerinodal growth was assessed in node-positive
patients only.
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influence of DTC had particular relevance in classic prognostic
subgroups defined by the TNM staging system. In univariate analyses,
the prognostic significance of IMS-detected EpCAM-positive cells was
evident in TNM stage 3, whereas significant impact of ICC-detected
cytokeratin-positive cells was confined to TNM stage 2 (Figure 2).
DISCUSSION
The main finding of this prospective study was that the presence of
DTC was a prognostic biomarker in this cohort of curatively
resected patients with CRC. Surprisingly, the use of IMS with an
anti-EpCAM antibody and ICC with anti-cytokeratin antibodies for
detection of tumour cells resulted in minimal detection overlap,
although results obtained with each method were associated with
outcome in distinct prognostic subgroups of CRC patients.
The detection rate of EpCAM- and cytokeratin-positive samples
in this study (in 17% and 12% of cases, respectively) was somewhat
lower than previously reported. A recent meta-analysis identified
only six studies that investigated the relevance of DTC in relation
to robust outcome parameters, such as metastasis-free and overall
survival (Rahbari et al, 2010). Of these studies, five utilised ICC
and one RT–PCR detection strategies in cohorts comprising
61–167 patients, and DTC were detected in 24–61% of cases.
Although suggesting a clinical relevance in CRC, the predictive
value of DTC could not be unambiguously determined based on
the results reported in these studies. The present work comprises one
of the largest CRC patient cohorts examined for the presence of DTC,
employing in parallel two distinct detection methods. Although
applying the combined results of two detection methods, only 21 of
the 55 patients that developed overt metastases could be identified.
Conversely, 46 of the 180 patients that did not develop metastatic
disease had DTC (combining results from the two methods), giving
test specificity and sensitivity for prediction of metastasis develop-
ment of 74% and 38%, respectively. This infers that in more than half
of the metastatic patients, tumour cells were either not present in BM
at diagnosis, or EpCAM and cytokeratin expression levels were below
the detection limit of the respective method. The finding that
detected cells in many cases did not give rise to secondary tumour
formation is in turn not surprising, given the known inefficiency of
the metastatic process (Chambers et al, 2002).
The high detection rate of DTC remains in intriguing contrast
to the relatively low incidence of overt bone metastases in CRC
(Chambers et al, 2002) (in the present study bone metastases were
reported in 3 of 55 patients with metastatic disease), suggesting that
BM may mirror dissemination of tumour cells to typical metastatic
sites (liver and lungs) or alternatively, represent a reservoir of tumour
cells able to initiate growth in secondary organs. The kinetics of overt
metastasis development (here observed to occur at median 15 months,
range 1–59 months after primary surgery) further suggests that DTC
may be representative of dormant tumour cells with the ability
to escape dormancy control to self-renew and differentiate upon
receiving an appropriate stimulus (McGowan et al, 2009).
While analysis of cytokeratin expression was chosen primarily
for being a hallmark of epithelial cellular origin, EpCAM expression
Table 4 Survival analyses of clinicopathological parameters and disseminated tumour cells in bone marrow
Univariate analysis (P-values, log rank test) Multivariate Cox regression analysis
a
Metastasis-free
survival
Disease-specific
survival
Overall
survival P-values
Hazard
ratio 95% CI
Gender 0.39 0.18 0.25
TNM o0.001 0.001 0.04 0.03
1
2 1.7 0.6–4.3
3 3.0 1.2–7.6
pT 0.06 0.06 0.20
pN o0.001 o0.001 0.002
Differentiation 0.20 0.20 0.45
Tumour localisation 0.02 0.10 0.13 0.02
Colon
Rectum 2.1 1.1–3.8
Lymphocyte infiltration 0.01 0.008 0.18 0.002
High
Intermediate 7.2 1.0–53.5
Low 13.0 1.7–99.3
Vascular invasion 0.01 0.03 0.18 0.009
Absent
Present 2.3 1.2–4.4
Neural invasion 0.11 0.02 0.50
Absent
Present
Perinodal growth
b 0.41 0.06 0.20
Immunomagnetic selection 0.049 0.03 0.02 0.007
Negative
Positive 2.4 1.3–4.5
Immunocytochemistry 0.03 0.002 0.06
Negative
Positive
Abbreviation: CI¼confidence interval.
aStepwise Cox regression analysis is shown for metastasis-free survival.
bPerinodal growth was assessed in node-positive patients only.
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functions as a homeotypic cell adhesion molecule in epithelial-
derived cells, EpCAM has been identified as a mitogenic signal
transducer and a stem cell marker (Maetzel et al, 2009; Munz et al,
2009). Thus, detection of EpCAM-positive tumour cells could signify
the presence of cells with stem-like properties in BM, potentially
contributing to the observed association with metastasis develop-
ment and patient survival. Interestingly, administration of adjuvant
chemotherapy did not influence metastasis development and survival
in this patient cohort (data not shown). Although the study design
could explain lack of power to detect differences that might still be
present, the data may also reflect that the chemotherapy regimen
used in the adjuvant setting at that time (5-fluorouracil and calcium
folinate) may have been inefficacious. It remains of vital importance
to identify and characterise cells responsible for metastatic relapse at
the molecular level, with the potential reward of identifying strategies
to target therapy towards the prolongation of dormancy or to attain
cell death (Epstein, 2005).
The low degree of positive overlap observed between the two
detection methods are in accordance with a recent study of 391 early
breast cancer patients, in which positive diagnostic overlap of only
3.2% was observed when ICC was performed using two different
pan-anti-cytokeratin antibodies, and distinct clinical implications
were associated with each antibody (Effenberger et al, 2011). In our
study, the presence of EpCAM- and cytokeratin-positive cells were
prognostic predictors in separate subgroups of CRC patients, in
TNM stages 3 and 2, respectively. It is difficult to provide a
biological explanation for this finding, and a likely cause could be
the low number of cases remaining for calculations in the subgroup
analyses. Substantiating the findings of these clinical trials are
studies characterising single or small numbers of DTC reporting
considerable heterogeneity with respect to genotypic and pheno-
typic properties of cells from the same individual, reflecting the
heterogeneity of the primary tumour (Gangnus et al, 2004). Thus, a
possible explanation for the lack of overlap between methods could
be the presence of subpopulations of tumour cells in BM with
distinct molecular characteristics, and to our knowledge, this is the
first report to demonstrate clinical impact of such findings in CRC.
Even counting for publication bias, the number of reports
supporting a clinical relevance for DTC in solid tumours is
remarkable, comprising most solid tumour forms (Pantel et al,
2009). Thus, it seems probable that tumour cells are detected,
although for most analytical methods, actual proof cannot be
provided for each detected cell. The present results add to the
evidence suggesting a role for DTC detection as a biomarker in
CRC. However, although biologically interesting, the variable
results obtained with different detection methods raise more
questions than are answered, rendering available technology
immature to the extent that it cannot be implemented in routine
clinical practice at present. Emerging results from characterisation
studies as well as from clinical trials like our own suggest
that a detection method suitable for clinical use should be able to
account for the apparent heterogeneity of DTC and its relevance in
the clinical setting. To address these questions, DTC detection
using a range of detection methods should be included in
future clinical trials, preferably in the adjuvant setting. This would
allow assessment of predictive robustness on a larger scale,
determination of potential associations with treatment response as
well as facilitate studies of relevant subpopulations of tumour cells
with the possibility of correlating results to clinical parameters.
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Figure 1 Kaplan–Meier survival plots demonstrating the association between the presence of disseminated tumour cells in bone marrow and survival
end points. Immunomagnetic selection (IMS) with an anti-EpCAM antibody and (A) metastasis-free (B) overall survival. Immunocytochemistry (ICC) with
anti-cytokeratin antibody and (C) metastasis-free and (D) overall survival.
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Figure 2 Kaplan–Meier survival plots demonstrating the association between the presence of disseminated tumour cells in bone marrow and metastasis-
free survival in stage subgroups at diagnosis. Immunomagnetic selection (IMS) in TNM stages 1 (A), 2 (B) and 3 (C). Immunocytochemistry (ICC) in
TNM stages 1 (D), 2 (E) and 3 (F).
DTC as a prognostic biomarker in CRC
K Flatmark et al
1439
British Journal of Cancer (2011) 104(9), 1434–1439 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s